drugset / Trial / NCT02062645

Study of Efficacy and Safety of CVAA489 in Hypertensive Patients

NCT02062645

Phase 4 Completed 115 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts. It is hypothesized that, in that population, amlodipine/valsartan will be effective at the same rate of blood pressure (BP) control rate as expected from literature.

Timeline

Start
2014-02
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Amlodipine Other / unclassified 10 mg
Subject Valsartan Small molecule 160 mg